Bubrežna disfunkcija kod bolesnika sa akutnom dekompenzacijom srčane slabosti
Sažetak
Uvod/Cilj. Bubrežna disfunkcija se često javlja kod bolesnika sa srčanom slabošću, predstavlja loš prognostički faktor i povezana je sa porastom mortaliteta kod ovih bolesnika. Cilj istraživanja je bio da se utvrde faktori rizika povezani sa razvojem bubrežne disfunkcije kod bolesnika sa akutnom dekompenzacijom srčane slabosti. Metode. Istraživanjem je obuhvaćeno 330 bolesnika sa akutnom dekompenzacijom srčane slabosti. Bolesnici koji su razvili bubrežnu disfunkciju (n = 215 ispitanika, starosti 72,4 ± 9,8 godina) činili su kliničku grupu, a bolesnici bez bubrežne disfunkcije (n = 115 ispitanika, starosti 59,8 ±11,7 godina) bili su kontrolna grupa. Kod ispitanika kliničke grupe analizirani su sledeći parametri: godine starosti, pol, lipidni status, koncentracija elektrolita u plazmi, prisustvo pušenja i hipertenzije i tip srčane slabosti. Korišćena je logistička regresija za izračunavanje odds ratio (OR) i 95% intervala poverenja za razvoj bubrežne disfunkcije kod ovih bolesnika. Rezultati. Bubrežna disfunkcija je ustanovljena kod 65,2% bolesnika sa srčanom slabošću. Pokazano je da su se kao značajni faktori rizika od razvoja bubrežne disfunkcije izdvojili starost ispitanika (OR = 1,6; p < 0,05), porast koncentracije ukupnog holesterola, > 5,2 mmol/L (OR = 1,6; p < 0,05), hiponatrijemija, < 135 mmol/L, (OR = 2,8; p < 0,01), pušenje (OR = 3,9; p < 0,01), hipertenzija (OR = 2,0; p < 0,05) i postojanje srčane slabosti sa smanjenom ejekcionom frakcijom (OR = 1,3; p < 0,01). Srčana slabost sa očuvanom ejekcionom frakcijom, hipokalijemija, < 3,5 mmol/L, visoka koncentracija triglicerida u plazmi, > 1,7 mmol/L i pol ispitanika nisu pokazali statistički značaj za razvoj bubrežne disfunkcije. Zaključak. Godine starosti, povišene vrednosti totalnog holesterola, hiponatrijemija, pušenje, hipertenzija i smanjenje ejekcione frakcije značajni su i nezavisni faktori rizika od razvoja bubrežne disfunkcije kod bolesnika sa srčanom slabošću. Poređenjem prediktivnih vrednosti, godine starosti bi mogle da budu najznačajniji faktor rizika za ranu identifikaciju bolesnika koji su pod povećanim rizikom od razvoja bubrežnog oštećenja.
Reference
Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. POSH investigators. Prevalence and impact of worsening re-nal function in patients hospitalized with decompensated heart failure: Results of the prospective outcomes study in heart fail¬ure (POSH). Eur Heart J 2006; 27(10): 1216–22.
Belziti CA, Bagnati R, Ledesma P, Vulcano N, Fernández S. Wors¬ening renal function in patients admitted with acute de-com¬pensated heart failure: Incidence, risk factors and prog-nostic implications. Rev Esp Cardiol 2010; 63(3): 294–302.
Damman K, Valente MA, Voors AA, Connor CO, Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analy¬sis. Eur Heart J 2014; 35(7): 455–69.
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bag-shaw SM, et al. Cardio-renal syndromes: report from the con-sensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31(6): 703–11.
Choudhary R, Gopal D, Kipper BA, De La Parra Landa A, Ara-min H, Lee E, et al. Cardiorenal biomarkers in acute heart failure. J Geriatr Cardiol 2012; 9(3): 292–304.
Maeder TM, Rickli H, Pfisterer ME, Muzzarelli S, Ammann P, Fehr T, et al. Incidence, clinical predictors, and prognostic im-pact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J 2012; 16(3)3: 407–14, 414.e1.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19): 2388–442.
Chavey WE 2nd, Blaum CS, Bleske BE, Harrison RV, Kesterson S, Nicklas JM. Guideline for the management of heart failure caused by systolic dysfunction: Part I. Guideline development, etiology and diagnosis. Am Fam Physician 2001; 64(5): 769–74.
Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, et al. Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic signif-i¬cance. Eur J Heart Fail 2008; 10(2): 188–95.
O’Meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB, McDonagh TA. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail 2006; 8(1): 63–7.
Ministry of Health of the Republic of Serbia. Republic profe-sional board for producing and implementation of guidelines of good clinical practice. National Guideline of Good Clinical Practice for Diagnosis and Treatment of Lipid Disorders. Bel-grade: Agency for Accreditation of Health Care, Institutions of Serbia; Available from: http://www.zdravlje.gov.rs/downloads/2011/Decembar/Vodici/Vodic%20za%20dijagnostikovanje%20i%20lecenje%20lipidskih%20poremecaja.pdf (Serbian)
Shiba N, Shimokawa H. Chronic kidney disease and heart fail-ure: Bidirectional close link and common therapeutic goal. J Cardiol 2011; 57(1): 8–17.
Giamouzis G, Kalogeropoulos AP, Butler J, Karayannis G, Geor-giopou¬lou VV, Skoularigis J, et al. Epidemiology and importance of renal dysfunction in heart failure patients. Curr Heart Fail Rep 2013; 10(4): 411–20.
Carubelli V, Metra M, Lombardi C, Bettari L, Bugatti S, Lazza-rini V, et al. Renal dysfunction in acute heart failure: epide-miology, mechanisms and assessment. Heart Fail Rev 2012; 17(2): 271–82.
Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device ther¬apy in heart failure patients with chronic kidney disease. J Am Coll Cardiol 2011; 58(9): 889–96.
Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymp¬tomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35(3): 681–9.
Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an an¬giotensin receptor blocker in addition to an angiotensin-con¬verting enzyme inhibitor in patients with moderate to se-vere heart failure. Circulation 2009; 120(16): 1577–84.
Sun WY, Reiser IW, Chou S. Risk factors for acute renal insuf-fi¬ciency induced by diuretics in patients with congestive heart failure. Am J Kidney Dis 2006; 47(5): 798–808.
Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, et al. Cardiorenal interactions: insights from the ES-CAPE trial. J Am Coll Cardiol 2008; 51(13): 1268–74.
Suzuki H, Kondo K. Chronic kidney disease in postmenopausal women. Hypertens Res 2012; 35(2): 142–7.
Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121(23): 2592–600.
Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4(12): 2013–26.
Peters MA, Perry L, Hooker CA, Howard B, Neilly MD, Seshadri N, et al. Extracellular fluid volume and glomerular filtration rate in 1878 healthy potential renal transplant donors: effects of age, gender, obesity and scaling. Nephrol Dial Transplant 2012; 27(4): 1429–37.